Restless Leg Syndrome - Leonard Weinstock, MD (2021 Conference) (LDN, low dose naltrexone)

This lecture starts with the known and newer pathophysiology to try to uncover new ways of treating restless legs syndrome (RLS). Using case studies, he links RLS with small intestinal bacterial overgrowth (SIBO), low iron, and other autoimmune disorders. Treatment examples are provided

 

Atopic Dermatitis - Pamela Smith, MD, MS (2021 Conference) (LDN, low dose naltrexone)

Atopic dermatitis is a hereditary skin disorder, and the most common form of eczema. Dr. Smith reviews the pathophysiology and diagnostic criteria for atopic dermatitis, as well as some causes.

 

Nuts and Bolts of The Thyroid Gland: Therapeutic Targets by Sarah Zielsdorf, MD (2021 Conference) (LDN, low dose naltrexone)

 

Drug Resistant Depression - Elizabeth Livengood, NMD (2021 Conference) (LDN, low dose naltrexone)

Dr. Elizabeth Livengood’s presentation is on identifying different causes of depression, identifying depression, hyperthyroidism connections, identifying patient profiles who fit these descriptions, and understanding how to treat them. 

 

History, Pharmacology and Mechanism - Stephen Dickson, BSC (hons) MRPharmS (2021 Conference) (LDN, low dose naltrexone)

LDN Research Trust 2021 Conference - Friday Morning

 

Leonard Weinstock, MD - Inflammatory Bowel Disease I (2017 Conference) (LDN, low dose naltrexone)

 

Darin Ingels, ND - LDN and Children (2017 Conference) (LDN, low dose naltrexone)

Research on LDN in children shows it is safe with low side effects. Studies where LDN was used successfully in children: 2 with Crohn’s, 2 with autism, 1 with CRPS. His cases: autism; Hashimoto’s; IBS.

 

Sajad Zalzala, MD - What Patients Need to Know About Telemedicine (2019 Conference) (LDN, low dose naltrexone)

Sajad Zalzala, MD discusses what telemedicine is, its use and benefits, and about using LDN Direct telemedicine/LDN prescription business. Some telemedicine regulations are presented, as well as common conditions treated with LDN

 

Michael Ruscio, DC - The Gut-Thyroid Connection, Profound but Under-Appreciated (2019 Conference) (LDN, low dose naltrexone)

 

Leonard Weinstock, MD - Mast cell activation syndrome and potential role for LDN (2019 Conference) (LDN, low dose naltrexone)

Leonard Weinstock, MD discusses LDN  for MCAS and SIBO at the LDN 2019 Conference. He discusses the etiology, symptoms, testing, and therapy for MCAS, SIBO, and POTS; and presents related cases.